Lipella Reveals Receipt Of FDA Type-C Meeting Guidance Regarding LP-10 (Liposomal Tacrolimus) Clinical Program; Plans To Advance Lead Product Candidate To Phase 2b

5/21/24 8:05:48 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LIPO alert in real time by email

Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024.

Lipella's Chief Medical Officer, Dr. Michael Chancellor, stated, "We can now proceed with the confidence that our Phase 2b study design can successfully meet its regulatory objectives. This clarity significantly advances our value proposition."

Get the next $LIPO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIPO

Date	Price Target	Rating	Analyst

More analyst ratings

$LIPO
Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all p
11/21/24 5:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles. The patent's claims cover Lipella's method of using metastable liposomes to deliver th
11/12/24 5:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current tra
11/1/24 4:30:00 PM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
7/12/24 1:15:05 PM ET
$ACHR
$AGRI
$ASPI
$AZ
Aerospace
Industrials
Metal Fabrications
Major Chemicals
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter sales and issued guidance. Ericsson reported a second-quarter loss of 31 cents per share, compared to year-ago earnings of 7 cents per share. The company reported quarterly sales of $5.59 billion which beat the analyst consensus estimate of $5.36 billion, according to data from Benzinga Pro. Ericsson shares jumped 4.3% to $6.66 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Sentage Holdings Inc. (NASDAQ:SNTG) rose 85.6% to $4.27 in pre-market trading after gaining around 5% on
7/12/24 5:35:41 AM ET
$AGRI
$ASPI
$ATCH
$BDRX
Metal Fabrications
Industrials
Major Chemicals
Finance: Consumer Services
Lipella Pharmaceuticals Completes Site Initiation Visit For Phase 2a Trial Of LP-310 In Oral Lichen Planus; Clinical Testing Of LP-310 Expected To Commence In Mid 2024
5/31/24 8:04:23 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care

Lipella Reveals Receipt Of FDA Type-C Meeting Guidance Regarding LP-10 (Liposomal Tacrolimus) Clinical Program; Plans To Advance Lead Product Candidate To Phase 2b

Chat with this insight

Recent Analyst Ratings for
$LIPO

$LIPO
Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

$LIPO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

SEC Form 4 filed by Pruchnic Ryan

SEC Form 4 filed by Yoshimura Naoki

$LIPO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

$LIPO
SEC Filings

SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SEC Form PRE 14A filed by Lipella Pharmaceuticals Inc.

$LIPO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

$LIPO
Market Insights

Live Market Insights

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Lipella Pharmaceuticals Completes Site Initiation Visit For Phase 2a Trial Of LP-310 In Oral Lichen Planus; Clinical Testing Of LP-310 Expected To Commence In Mid 2024

Lipella Reveals Receipt Of FDA Type-C Meeting Guidance Regarding LP-10 (Liposomal Tacrolimus) Clinical Program; Plans To Advance Lead Product Candidate To Phase 2b

Chat with this insight

Recent Analyst Ratings for $LIPO

$LIPO Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

$LIPO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

SEC Form 4 filed by Pruchnic Ryan

SEC Form 4 filed by Yoshimura Naoki

$LIPO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

$LIPO SEC Filings

SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SEC Form PRE 14A filed by Lipella Pharmaceuticals Inc.

$LIPO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

$LIPO Market Insights

Live Market Insights

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Lipella Pharmaceuticals Completes Site Initiation Visit For Phase 2a Trial Of LP-310 In Oral Lichen Planus; Clinical Testing Of LP-310 Expected To Commence In Mid 2024

Recent Analyst Ratings for
$LIPO

$LIPO
Press Releases

$LIPO
Insider Trading

$LIPO
Large Ownership Changes

$LIPO
SEC Filings

$LIPO
Insider Purchases

$LIPO
Market Insights